Walleye Capital’s Aerie Pharmaceuticals AERI Stock Holding History

Walleye Capital’s Portfolio AERI Stock Details AERI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-67,310	Closed	-$1.02M	–	4026
2022 Q3	$1.02M	Sell	67,310 -564,180	-89%	-$6.56M	0.02%	958
2022 Q2	$4.74M	Buy	631,490 +362,380	+135%	+$2.55M	0.13%	183
2022 Q1	$2.45M	Sell	269,110 -107,213	-28%	-$826K	0.07%	316
2021 Q4	$2.64M	Buy	376,323 +103,259	+38%	+$1.08M	0.08%	263
2021 Q3	$3.11K	Buy	+273,064	New	+$3.99M	0.09%	154
2021 Q1	–	Sell	-77,800	Closed	-$1.05K	–	1437
2020 Q4	$1.05K	Buy	+77,800	New	+$940K	0.07%	276
2019 Q3	–	Sell	-10,003	Closed	-$229K	–	2369
2019 Q2	$296K	Buy	+10,003	New	+$385K	0.03%	741

Walleye Capital's AERI Position: Q4 2022 in Review

Walleye Capital sold out of Aerie Pharmaceuticals (AERI) in Q4 2022, closing a stake of 67,310 shares — an estimated $1.02M sold.

Walleye Capital first reported a position in AERI in Q2 2019 and held it in 7 quarters. The position peaked at $4.74M in Q2 2022. 0 funds tracked by Wall St. Rank hold AERI as of Q4 2022.

Walleye Capital reported no remaining Aerie Pharmaceuticals position as of Q4 2022 after selling out during the quarter.
Walleye Capital sold 67,310 Aerie Pharmaceuticals shares in Q4 2022, an estimated $1.02M.
Walleye Capital first reported a position in Aerie Pharmaceuticals in Q2 2019 and held it in 7 quarters.
Walleye Capital's Aerie Pharmaceuticals position peaked at $4.74M in Q2 2022.
0 funds tracked by Wall St. Rank held Aerie Pharmaceuticals as of Q4 2022.

Based on Walleye Capital's 13F filing for Q4 2022, filed 14 Feb 2023.